vaccines across the world triggered by the Covid-19 pandemic and the recent reports of outbreaks of monkeypox across the world. The safety concerns, efficacy and effective distribution of vaccines have prompted biotech companies to invest in further research for the production of more effective biopharmaceutical products and those that are specific in their therapeutic delivery such as the ongoing research nasal vaccines for Covid-19.
Genomics Resource Centre Berhad and Ajlan & Bros Medical Company MoU also includes Ajlan representing Malaysian Genomics for genetic screening tests with marketing and distribution for mesenchymal stem cell and exosome products together with exploring commercial research and development opportunities for genome sequencing and analysis in the Middle East and the North Africa region for agriculture, aquaculture, plantations, healthcare and the industrial biotechnology sectors. Mesenchymal stem cells are commonly used in regenerative medicine and used to treat a variety of conditions such as autoimmune disorders, stroke, meniscus injury, limb ischemia, graft-versus-host disease and cancer. Exosome are cell to cell communicators and their products are widely used for analysis of RNA and proteins together with the treatment of cardiovascular and regenerative conditions such as arthritis, neurological diseases and certain cancers. The significance of the biotechnology industry has been recognized across the world and commonwealth nations such as India, Singapore and Malaysia have been at the forefront in Asia together with more established markets for the biotechnology industry in the UK, Canada, Australia and New Zealand.
